167 related articles for article (PubMed ID: 23960440)
1. Serum level of interleukin-33 and soluble ST2 and their association with disease activity in patients with Behcet's disease.
Kim DJ; Baek SY; Park MK; Park KS; Lee JH; Park SH; Kim HY; Kwok SK
J Korean Med Sci; 2013 Aug; 28(8):1145-53. PubMed ID: 23960440
[TBL] [Abstract][Full Text] [Related]
2. Serum levels of IL-33 and soluble ST2 and their association with disease activity in systemic lupus erythematosus.
Mok MY; Huang FP; Ip WK; Lo Y; Wong FY; Chan EY; Lam KF; Xu D
Rheumatology (Oxford); 2010 Mar; 49(3):520-7. PubMed ID: 20026564
[TBL] [Abstract][Full Text] [Related]
3. Increased serum interleukin-32 levels in patients with Behçet's disease.
Ha YJ; Park JS; Kang MI; Lee SK; Park YB; Lee SW
Int J Rheum Dis; 2018 Dec; 21(12):2167-2174. PubMed ID: 28378461
[TBL] [Abstract][Full Text] [Related]
4. Serum IL-33 levels and skin mRNA expression in Behçet's disease.
Hamzaoui K; Kaabachi W; Fazaa B; Zakraoui L; Mili-Boussen I; Haj-Sassi F
Clin Exp Rheumatol; 2013; 31(3 Suppl 77):6-14. PubMed ID: 23464866
[TBL] [Abstract][Full Text] [Related]
5. Soluble ST2 as a marker of disease activity in systemic juvenile idiopathic arthritis.
Ishikawa S; Shimizu M; Ueno K; Sugimoto N; Yachie A
Cytokine; 2013 May; 62(2):272-7. PubMed ID: 23561929
[TBL] [Abstract][Full Text] [Related]
6. Characterization of interleukin-33 and soluble ST2 in serum and their association with disease severity in patients with chronic kidney disease.
Bao YS; Na SP; Zhang P; Jia XB; Liu RC; Yu CY; Mu SH; Xie RJ
J Clin Immunol; 2012 Jun; 32(3):587-94. PubMed ID: 22203232
[TBL] [Abstract][Full Text] [Related]
7. Serum Interleukin-33 in Behcet's Disease: Its Relation to Disease Activity and Clinical Manifestations.
Fawzy RM; Said EA; Mohamed SM; Fouad NA; Akl EM
Egypt J Immunol; 2015 Jun; 22(2):1-8. PubMed ID: 28502139
[TBL] [Abstract][Full Text] [Related]
8. The levels of soluble ST2 in sera and bullous fluid from patients with bullous pemphigoid.
Wakatabi K; Komine M; Meephansan J; Matsuyama Y; Tsuda H; Tominaga S; Ohtsuki M
Eur J Dermatol; 2012; 22(3):333-6. PubMed ID: 22494834
[TBL] [Abstract][Full Text] [Related]
9. The Interleukin 33/ST2 axis in patients with primary Sjögren syndrome: expression in serum and salivary glands, and the clinical association.
Jung SM; Lee J; Baek SY; Lee JH; Lee J; Park KS; Park SH; Kim HY; Kwok SK
J Rheumatol; 2015 Feb; 42(2):264-71. PubMed ID: 25512474
[TBL] [Abstract][Full Text] [Related]
10. Elevated serum level of IL-33 and sST2 in patients with ankylosing spondylitis: associated with disease activity and vascular endothelial growth factor.
Li XL; Lin TT; Qi CY; Yuan L; Xia LP; Shen H; Lu J
J Investig Med; 2013 Jun; 61(5):848-51. PubMed ID: 23552178
[TBL] [Abstract][Full Text] [Related]
11. Serum levels of alpha-1 acid glycoprotein and pentraxin 3 in patients with Behçet's disease and relationship with disease activity.
Yazmalar L; Batmaz İ; Sula B; Alpaycı M; Aydın F; Türkçü F; Yıldız M; Kaplan İ; Bozkurt M; Dağlı AZ; Burkan YK; Sarıyıldız MA
Int J Dermatol; 2015 Oct; 54(10):e394-400. PubMed ID: 26147939
[TBL] [Abstract][Full Text] [Related]
12. Serum levels of soluble ST2 and interleukin-33 in patients with dermatomyositis and polymyositis.
Yuan L; Yao L; Zhao L; Xia L; Shen H; Lu J
Clin Exp Rheumatol; 2013; 31(3):428-32. PubMed ID: 23485578
[TBL] [Abstract][Full Text] [Related]
13. ST2 and IL-33 in pregnancy and pre-eclampsia.
Granne I; Southcombe JH; Snider JV; Tannetta DS; Child T; Redman CW; Sargent IL
PLoS One; 2011; 6(9):e24463. PubMed ID: 21949719
[TBL] [Abstract][Full Text] [Related]
14. Soluble ST2 and interleukin-33 levels in coronary artery disease: relation to disease activity and adverse outcome.
Demyanets S; Speidl WS; Tentzeris I; Jarai R; Katsaros KM; Farhan S; Krychtiuk KA; Wonnerth A; Weiss TW; Huber K; Wojta J
PLoS One; 2014; 9(4):e95055. PubMed ID: 24751794
[TBL] [Abstract][Full Text] [Related]
15. Reduced levels of interleukin 33 and increased levels of soluble ST2 in subjects with amyotrophic lateral sclerosis.
Lin CY; Pfluger CM; Henderson RD; McCombe PA
J Neuroimmunol; 2012 Aug; 249(1-2):93-5. PubMed ID: 22633272
[TBL] [Abstract][Full Text] [Related]
16. Serum soluble ST2 is associated with ER-positive breast cancer.
Lu DP; Zhou XY; Yao LT; Liu CG; Ma W; Jin F; Wu YF
BMC Cancer; 2014 Mar; 14():198. PubMed ID: 24636276
[TBL] [Abstract][Full Text] [Related]
17. Potential contribution of interleukin-33 to the development of interstitial lung disease in patients with primary Sjogren's Syndrome.
Zhao L; Yao L; Yuan L; Xia L; Shen H; Lu J
Cytokine; 2013 Oct; 64(1):22-4. PubMed ID: 23910012
[TBL] [Abstract][Full Text] [Related]
18. Correlation between soluble triggering receptor expressed on myeloid cells-1 and endoscopic activity in intestinal Behçet's disease.
Lee HJ; Shin HS; Jang HW; Kim SW; Park SJ; Hong SP; Kim TI; Kim WH; Cheon JH
Yonsei Med J; 2014 Jul; 55(4):960-6. PubMed ID: 24954324
[TBL] [Abstract][Full Text] [Related]
19. An Exploration of Some Predictors of Quality of Life-Related to the Innate Immune System, Inflammation, and Disease Activity in Patients with Behcet's Syndrome: An Analytical Cross-sectional Study.
Faghfouri AH; Shoura SMS; Papi S; Khabbazi A; Baradaran B; Badpeyma M; Faghfuri E
Curr Rheumatol Rev; 2024; 20(2):200-207. PubMed ID: 37691223
[TBL] [Abstract][Full Text] [Related]
20. Soluble ST2: a new and promising activity marker in ulcerative colitis.
Díaz-Jiménez D; Núñez LE; Beltrán CJ; Candia E; Suazo C; Alvarez-Lobos M; González MJ; Hermoso MA; Quera R
World J Gastroenterol; 2011 May; 17(17):2181-90. PubMed ID: 21633527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
